Analysis of the SYSDIET Healthy Nordic Diet randomized trial based on metabolic profiling reveal beneficial effects on glucose metabolism and blood lipids

Clin Nutr. 2022 Feb;41(2):441-451. doi: 10.1016/j.clnu.2021.12.031. Epub 2021 Dec 25.

Abstract

Background & aims: Intake assessment in multicenter trials is challenging, yet important for accurate outcome evaluation. The present study aimed to characterize a multicenter randomized controlled trial with a healthy Nordic diet (HND) compared to a Control diet (CD) by plasma and urine metabolic profiles and to associate them with cardiometabolic markers.

Methods: During 18-24 weeks of intervention, 200 participants with metabolic syndrome were advised at six centres to eat either HND (e.g. whole-grain products, berries, rapeseed oil, fish and low-fat dairy) or CD while being weight stable. Of these 166/159 completers delivered blood/urine samples. Metabolic profiles of fasting plasma and 24 h pooled urine were analysed to identify characteristic diet-related patterns. Principal components analysis (PCA) scores (i.e. PC1 and PC2 scores) were used to test their combined effect on blood glucose response (primary endpoint), serum lipoproteins, triglycerides, and inflammatory markers.

Results: The profiles distinguished HND and CD with AUC of 0.96 ± 0.03 and 0.93 ± 0.02 for plasma and urine, respectively, with limited heterogeneity between centers, reflecting markers of key foods. Markers of fish, whole grain and polyunsaturated lipids characterized HND, while CD was reflected by lipids containing palmitoleic acid. The PC1 scores of plasma metabolites characterizing the intervention is associated with HDL (β = 0.05; 95% CI: 0.02, 0.08; P = 0.001) and triglycerides (β = -0.06; 95% CI: -0.09, -0.03; P < 0.001). PC2 scores were related with glucose metabolism (2 h Glucose, β = 0.1; 95% CI: 0.05, 0.15; P < 0.001), LDL (β = 0.06; 95% CI: 0.01, 0.1; P = 0.02) and triglycerides (β = 0.11; 95% CI: 0.06, 0.15; P < 0.001). For urine, the scores were related with LDL cholesterol.

Conclusions: Plasma and urine metabolite profiles from SYSDIET reflected good compliance with dietary recommendations across the region. The scores of metabolites characterizing the diets associated with outcomes related with cardio-metabolic risk. Our analysis therefore offers a novel way to approach a per protocol analysis with a balanced compliance assessment in larger multicentre dietary trials. The study was registered at clinicaltrials.gov with NCT00992641.

Keywords: Glucose and lipid metabolism; Healthy Nordic diet; LC–MS metabolomics; Plasma metabolite scores; Randomized controlled trial.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Area Under Curve
  • Biomarkers / blood
  • Biomarkers / urine
  • Blood Glucose / metabolism*
  • Cardiometabolic Risk Factors
  • Diet, Healthy / methods*
  • Eating / physiology
  • Fasting / blood
  • Fasting / urine
  • Female
  • Humans
  • Inflammation Mediators / blood
  • Lipids / blood
  • Lipoproteins / blood
  • Male
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / diet therapy*
  • Metabolomics / methods*
  • Middle Aged
  • Nutrition Assessment*
  • Overweight / complications
  • Overweight / diet therapy
  • Principal Component Analysis
  • Randomized Controlled Trials as Topic
  • Scandinavian and Nordic Countries
  • Triglycerides / blood

Substances

  • Biomarkers
  • Blood Glucose
  • Inflammation Mediators
  • Lipids
  • Lipoproteins
  • Triglycerides

Associated data

  • ClinicalTrials.gov/NCT00992641